

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,714
				371(c) Date	June 4, 2007
				First Named Inventor	Jane K. Relton
				Art Unit	1646
				Examiner Name	WEGERT, Sandra L.
Sheet	1	of	1	Attorney Docket Number	2681.0450001/EJH/JBF

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL44	Connor, B., <i>et al.</i> , "Adenoviral Vector-Mediated Delivery of Glial Cell Line-Derived Neurotrophic Factor Provides Neuroprotection in the Aged Parkinsonian Rat," <i>Clin. Exp. Pharma. Physiol.</i> 28:896-900, Blackwell Publishing Asia Pty Ltd. (2001)	
	NPL45	MacDermid, VE, <i>et al.</i> , "Plasticity of descending dorsal root projections after partial spinal cord deafferentation and the use of anti-inhibitory strategies to myelin inhibitory proteins," Neuroscience 2003 Abstract No. 42.13, Society for Neuroscience (2003)	
	NPL46	Muramatsu, S., <i>et al.</i> , "Gene therapy of Parkinson's disease: AAV vectors for delivery of therapeutic genes into mammalian brains," <i>Inflammation and Regeneration</i> 23(4):218-222 (2003)	
	NPL47	Murray, T.K., <i>et al.</i> , "LY503430, a Novel α -Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson's Disease," <i>J. Pharma. Exp. Therapeutics</i> 306:752-62, American Society for Pharmacology and Experimental Therapeutics (2003)	

1316885_1.DOC

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.